Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3-Reference-Cited by-同舟云学术

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

Published:2022-12-28 Issue:3 Volume:28 Page:e167-e170
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Meza Luis¹^ORCID,McDermott David F²,Escudier Bernard³,Hutson Thomas E⁴,Porta Camillo⁵,Verzoni Elena⁶,Atkins Michael B⁷,Kasturi Vijay⁸,Pal Sumanta K¹,Rini Brian⁹

Affiliation:

1. Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA

2. Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center , Boston, MA , USA

3. Department of Medical Oncology, Gustave Roussy , Villejuif , France

4. Department of Hematology and Medical Oncology, Texas A&M University College of Medicine , Bryan, TX , USA

5. Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro and Policlinico Consorziale di Bari , Bari , Italy

6. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori , Milan , Italy

7. Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center , Washington, DC , USA

8. Clinical Development and Medical Affairs, Aveo Oncology , Boston, MA , USA

9. Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center , Nashville, TN , USA

Abstract

Abstract Background In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib. Methods We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety. Results Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib. Conclusions Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.

Funder

Aveo Oncology

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/28/3/e167/49806783/oyac255.pdf

Reference8 articles.

1. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study;Rini;Lancet Oncol.,2020

2. Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC;Pal;J Clin Oncol.,2021

3. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors;McTigue;Proc Natl Acad Sci USA.,2012

4. Resistance to targeted therapy in renal-cell carcinoma;Rini;Lancet Oncol.,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma;Cureus;2023-03-02